Progenics Falls After Two Deaths in Cancer Drug Trial

Progenics Pharmaceuticals Inc. (PGNX) fell the most in 14 months after a study summary showed two patients died of sepsis in a trial of the company’s experimental prostate cancer treatment.

Progenics tumbled 19 percent to $5.04 at 12:11 p.m. New York time, after losing as much as 20 percent for its biggest intraday drop since November 2012. The Tarrytown, New York-based company’s stock had doubled in the 12 months through yesterday.

The targeted chemotherapy treatment for prostate cancer is designed to act as a “Trojan horse,” remaining stable in the blood then releasing toxins once inside tumor cells, according to company’s website. The study abstract appears to show that even at a lower dose of the drug, PSMA-ADC, patients could experience life-threatening levels of toxicity, said Brian Klein, an analyst at New York-based Stifel Nicolaus & Co.

The deaths suggest that the drug has “a major impact on the immune system,” Klein said in a phone interview.

Progenics is scheduled to discuss the study tomorrow at the Genitourinary Cancers Symposium in San Francisco. A summary was posted on the symposium’s website, revealing the two deaths. A spokeswoman for Progenics didn’t immediately respond to a request to comment on the findings.

PSMA-ADC is a so-called antibody-drug conjugate, which uses an antibody to find and bind with a protein on the surface of prostate cancer cells then deliver a cancer-killing chemical. Sepsis is often the result of a blood or tissue infection that causes the immune system to attack the body in a way that can typically lead to multiple organ failure and death.

The drug appears to offer “little benefit versus the apparent toxicity,” Klein said in a research note to clients.

“We believe this compound does not demonstrate the necessary characteristics to move forward into late stage testing,” Klein, who has a hold rating on Progenics, said in the note.

To contact the reporter on this story: Caroline Chen in New York at

To contact the editor responsible for this story: Reg Gale at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.